Santen Pharmaceutical Co., Ltd. (SNPHF)
OTCMKTS
· Delayed Price · Currency is USD
10.53
-0.62 (-5.53%)
At close: Dec 9, 2024
Santen Pharmaceutical Revenue
Santen Pharmaceutical had revenue of 76.37B JPY in the quarter ending December 31, 2024, a decrease of -0.85%. This brings the company's revenue in the last twelve months to 301.91B, down -0.06% year-over-year. In the fiscal year ending March 31, 2024, Santen Pharmaceutical had annual revenue of 301.97B with 8.22% growth.
Revenue (ttm)
301.91B JPY
Revenue Growth
-0.06%
P/S Ratio
n/a
Revenue / Employee
80.64M JPY
Employees
3,744
Market Cap
3.23B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 301.97B | 22.93B | 8.22% |
| Mar 31, 2023 | 279.04B | 12.78B | 4.80% |
| Mar 31, 2022 | 266.26B | 16.65B | 6.67% |
| Mar 31, 2021 | 249.61B | 8.05B | 3.33% |
| Mar 31, 2020 | 241.56B | 7.53B | 3.22% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| BioStem Technologies | 210.49M |
Santen Pharmaceutical News
- 2 years ago - Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha